Published in Women's Health Weekly, December 25th, 2008
"Dose-dense EC (without the 5-FU) is not associated with pneumonitis, and dose-dense paclitaxel (alone) is feasible. Primary objective was feasibility. Patients with resectable breast cancer were enrolled, regardless of surgery status, tumor size, or nodal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly